Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1A46
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
1A46 is a trispecific T-cell engager antibody that simultaneously targets CD3 on cytotoxic T lymphocytes and CD19 and/or CD20 on B cells. By binding to these antigens, it redirects and activates cytotoxic T cells to recognize and kill malignant B cells expressing CD19 or CD20. The drug is being developed for the treatment of relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL), as well as other advanced malignancies with CD19 or CD20 expression. It is administered intravenously and has been evaluated in first-in-human phase I/II clinical trials in China and the US for hematologic cancers such as lymphoma and leukemia[1][2][3][4][5]. GSK has acquired global rights from Chimagen Biosciences with plans to expand development into autoimmune diseases like systemic lupus erythematosus (SLE) and lupus nephritis[7].
- Other names
- anti-CD3/CD19/CD20 trispecific antibody 1A46CMG1A46CMG-1A46CMG 1A46
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on 1A46.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1A46.